AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16458213 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire-assisted radial artery cannulation
Number of subjects: 100
Study 16458213 — intervention group
Group type: COMPARATOR
Intervention: Direct radial artery cannulation
Number of subjects: 100
Study 14613739 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms (General Health Questionnaire score >/=5)
Number of subjects: 1130
Study 14613739 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1130
Study 10639542 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine medical testing (electrocardiography, complete blood count, serum levels of electrolytes, urea nitrogen, creatinine, glucose) before cataract surgery
Number of subjects: 18189
Study 10639542 — intervention group
Group type: COMPARATOR
Intervention: No routine medical testing before cataract surgery
Number of subjects: 18189
Study 10639542 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine medical testing before cataract surgery
Number of subjects: 18189
Study 9366542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) solution
Number of subjects: 110
Study 9366542 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) preparations
Number of subjects: 110
Study 1583824 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 532
Study 1583824 — intervention group
Group type: COMPARATOR
Intervention: Heparin (H)
Number of subjects: 532
Study 1583824 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of ST-segment elevation by 50% after 2 hours of treatment
Number of subjects: 532
Study 4041324 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 20
Study 4041324 — intervention group
Group type: COMPARATOR
Intervention: 0.5% amethocaine
Number of subjects: 20
Study 30570839 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg after a high-fat meal
Number of subjects: 24
Study 30570839 — intervention group
Group type: COMPARATOR
Intervention: Brigatinib 180 mg after fasting
Number of subjects: 24
Study 30570839 — intervention group
Group type: COMPARATOR
Intervention: Treatment-emergent adverse events under fasted conditions
Number of subjects: 24
Study 30570839 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events under fed conditions
Number of subjects: 24
Study 30518514 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Well intervention
Number of subjects: 0
Study 30518514 — intervention group
Group type: EXPERIMENTAL
Intervention: SlowMo therapy (new intervention)
Number of subjects: 0
Study 26936074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 26936074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24550332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)‐boosted Elvitegravir (EVG/co) (150/150 mg) administered once daily for 10 days
Number of subjects: 20
Study 24550332 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 10)
Number of subjects: 20
Study 21727201 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma MMP-2 at 0 and 12 h
Number of subjects: 58
Study 21727201 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 and TIMP-2
Number of subjects: 58
Study 21727201 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-8, MMP-9 and MPO
Number of subjects: 58
Study 19953610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 20 mL of 0.75% ropivacaine
Number of subjects: 100
Study 19953610 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 100
Study 19953610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine group
Number of subjects: 100
Study 17179200 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (50 microg daily)
Number of subjects: 12
Study 17179200 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 12
Study 14693980 — intervention group
Group type: EXPERIMENTAL
Intervention: SU plus pioglitazone
Number of subjects: 639
Study 14693980 — intervention group
Group type: COMPARATOR
Intervention: SU plus metformin
Number of subjects: 639
Study 11576740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-avoidance beliefs about work
Number of subjects: 78
Study 11576740 — intervention group
Group type: COMPARATOR
Intervention: Initial evaluation measurements
Number of subjects: 78
Study 11576740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-avoidance beliefs
Number of subjects: 78
Study 9678311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of amyloid beta protein (Abeta42)
Number of subjects: 82
Study 9678311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of tau
Number of subjects: 82
Study 9678311 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification tree analysis comparing AD and NC subjects
Number of subjects: 82
Study 9678311 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF markers for autopsy follow-up
Number of subjects: 82
Study 9678311 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E epsilon4 allele dose
Number of subjects: 82
Study 9678311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination score
Number of subjects: 82
Study 9678311 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 82
Study 8036454 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg at 1830 h)
Number of subjects: 10
Study 8036454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2660379 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 0
Study 2660379 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 0
Study 30504715 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (DFX)
Number of subjects: 6
Study 30504715 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO)
Number of subjects: 6
Study 28885362 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lenses (BCL) application
Number of subjects: 30
Study 28885362 — intervention group
Group type: COMPARATOR
Intervention: No BCL application (control group)
Number of subjects: 30
Study 26837817 — intervention group
Group type: EXPERIMENTAL
Intervention: Values clarification condition
Number of subjects: 146
Study 26837817 — intervention group
Group type: COMPARATOR
Intervention: Active problem-solving control condition
Number of subjects: 146
Study 25433353 — intervention group
Group type: EXPERIMENTAL
Intervention: HM+ (telemonitored by the BIOTRONIK Home Monitoring® system)
Number of subjects: 198
Study 25433353 — intervention group
Group type: COMPARATOR
Intervention: HM- (standard outpatient visits)
Number of subjects: 198
Study 22381489 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity laser therapy (infrared radiation from a semiconductor diode laser with a wavelength of 810 nm), applied on days 0, 3, 7, and 14 in the first month, and thereafter on every 15th day until complete canine retraction was achieved.
Number of subjects: 20
Study 22381489 — intervention group
Group type: COMPARATOR
Intervention: Control side (no low-intensity laser therapy applied).
Number of subjects: 20
Study 21158963 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Material Style of Life (MSL) score (>12)
Number of subjects: 230
Study 21158963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate MSL score (8-12)
Number of subjects: 230
Study 21158963 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutrient-dense foods (NNDF)
Number of subjects: 230
Study 21158963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean frequencies of fruit and vegetables (FV) and traditional foods (TF) consumption
Number of subjects: 230
Study 17557769 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 42
Study 17557769 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 42
Study 15850883 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT + C-MIS
Number of subjects: 315
Study 15850883 — intervention group
Group type: COMPARATOR
Intervention: NRT
Number of subjects: 315
Study 12470136 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 234
Study 12470136 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angle-closure glaucoma (PACG)
Number of subjects: 234
Study 12470136 — intervention group
Group type: COMPARATOR
Intervention: Comparison between POAG and PACG
Number of subjects: 234
Study 9534293 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 89
Study 9534293 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 89
Study 9534293 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg + Hydrochlorothiazide 25 mg (L-HCTZ Group)
Number of subjects: 89
Study 9588918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose proton and photon irradiation (66.6 or 72 cobalt Gray equivalent, 1.8 CGE/day, 5 fractions/week)
Number of subjects: 96
Study 9588918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose proton and photon irradiation
Number of subjects: 96
Study 1927914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic low osmolar contrast agent ioxaglate (n = 50)
Number of subjects: 100
Study 1927914 — intervention group
Group type: COMPARATOR
Intervention: Nonionic low osmolar contrast media iohexol (n = 50)
Number of subjects: 100
Study 7051984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphamethoxazole
Number of subjects: 33
Study 7051984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30676838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose investigational Sabin IPV (group A)
Number of subjects: 600
Study 30676838 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose investigational Sabin IPV (group B)
Number of subjects: 600
Study 30676838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose investigational Sabin IPV (group C)
Number of subjects: 600
Study 30676838 — intervention group
Group type: COMPARATOR
Intervention: Control Salk IPV (group D)
Number of subjects: 600
Study 30676838 — intervention group
Group type: COMPARATOR
Intervention: Control Sabin IPV (group E)
Number of subjects: 600
Study 28424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Number of subjects: 499
Study 28424269 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 499
Study 27336050 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 124
Study 27336050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 124
Study 27336050 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 124
Study 27157293 — intervention group
Group type: EXPERIMENTAL
Intervention: 75mg/d clopidogrel in addition to 100mg acetylsalicylic acid (ASA) for 4 weeks
Number of subjects: 40
Study 27157293 — intervention group
Group type: COMPARATOR
Intervention: 100mg acetylsalicylic acid (ASA) and additional placebo for 4 weeks
Number of subjects: 40
Study 23500669 — intervention group
Group type: COMPARATOR
Intervention: Magnetoencephalographic Mu-modulations during observation of grasping movements in children with Asperger's syndrome.
Number of subjects: 0
Study 23500669 — intervention group
Group type: COMPARATOR
Intervention: Source localization of Mu-activity in the brain.
Number of subjects: 0
Study 23500669 — intervention group
Group type: COMPARATOR
Intervention: Correlation of brain activity with social competence.
Number of subjects: 0
Study 23500669 — intervention group
Group type: COMPARATOR
Intervention: Correlation with intellectual ability.
Number of subjects: 0
Study 20878446 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted dose-dense temozolomide therapy (100 mg/m² for 21 consecutive days of a 28-day cycle)
Number of subjects: 25
Study 20878446 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted dose-dense temozolomide therapy
Number of subjects: 25
Study 19170737 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (high dose = target 1.0 mg/kg/day)
Number of subjects: 68
Study 19170737 — intervention group
Group type: COMPARATOR
Intervention: Clobazam (low dose = target 0.25 mg/kg/day)
Number of subjects: 68
Study 19170737 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (high dose)
Number of subjects: 68
Study 19170737 — intervention group
Group type: COMPARATOR
Intervention: Clobazam (low dose)
Number of subjects: 68
Study 19170737 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (both doses)
Number of subjects: 68
Study 16442906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score with 0 points (no risk factors)
Number of subjects: 469
Study 16442906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score with 1 point (one risk factor)
Number of subjects: 469
Study 16442906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score with 2 points (two risk factors)
Number of subjects: 469
Study 16442906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score with >= 3 points (three or more risk factors)
Number of subjects: 469
Study 16442906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score >= 2
Number of subjects: 469
Study 16442906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score < 2
Number of subjects: 469
Study 14767877 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/d n3PUFA
Number of subjects: 80
Study 14767877 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/d AT
Number of subjects: 80
Study 14767877 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g n3PUFA + 800 IU/d AT
Number of subjects: 80
Study 14767877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11411195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Hep (10 micrograms dose)
Number of subjects: 524
Study 11411195 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (20 micrograms dose)
Number of subjects: 524
Study 10064661 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zafirlukast
Number of subjects: 39
Study 10064661 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zafirlukast
Number of subjects: 39
Study 10064661 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zafirlukast
Number of subjects: 39
Study 10064661 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg zafirlukast
Number of subjects: 39
Study 10064661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10064661 — intervention group
Group type: EXPERIMENTAL
Intervention: All zafirlukast doses
Number of subjects: 39
Study 7656832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (CMD) in combination with radiation therapy
Number of subjects: 0
Study 7656832 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study 2713323 — intervention group
Group type: EXPERIMENTAL
Intervention: External pin fixation
Number of subjects: 54
Study 2713323 — intervention group
Group type: COMPARATOR
Intervention: Transnasal Kirschner wire (K-wire) fixation
Number of subjects: 54
Study 728282 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 0
Study 728282 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0
Study 31378071 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 4597
Study 31378071 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery stenting
Number of subjects: 4597
Study 29074161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 362
Study 29074161 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept
Number of subjects: 362
Study 29074161 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline VALS in the better eye
Number of subjects: 362
Study 26527781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 164
Study 26527781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 23121470 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath® Series 5 videolaryngoscope
Number of subjects: 88
Study 23121470 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 88
Study 21816255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy
Number of subjects: 180
Study 21816255 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation
Number of subjects: 180
Study 19539180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate supplementation (six 1-g soft-gel capsules daily for 6 months)
Number of subjects: 87
Study 19539180 — intervention group
Group type: COMPARATOR
Intervention: Corn-oil capsules (same protocol as fish-oil group)
Number of subjects: 87
Study 17143946 — intervention group
Group type: EXPERIMENTAL
Intervention: Music played during the procedure
Number of subjects: 167
Study 17143946 — intervention group
Group type: COMPARATOR
Intervention: No music played
Number of subjects: 167
Study 15327613 — intervention group
Group type: EXPERIMENTAL
Intervention: Open colposuspension with sutures
Number of subjects: 240
Study 15327613 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic colposuspension with mesh and staples
Number of subjects: 240
Study 11514483 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct coronary stenting without balloon predilatation (group I)
Number of subjects: 396
Study 11514483 — intervention group
Group type: COMPARATOR
Intervention: Stenting preceded by balloon predilatation (group II)
Number of subjects: 396
Study 11514483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 396
Study 9028091 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural lidocaine (1% lidocaine 5ml.h‐1) during surgery combined with preoperative epidural morphine (2 mg)
Number of subjects: 20
Study 9028091 — intervention group
Group type: COMPARATOR
Intervention: Preoperative epidural morphine (2 mg) alone
Number of subjects: 20
Study 9480236 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy pregnant women
Number of subjects: 65
Study 9480236 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-pregnant women (control)
Number of subjects: 65
Study 2565998 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed hepatitis A vaccine with aluminium hydroxide as adjuvant
Number of subjects: 32
Study 2565998 — intervention group
Group type: COMPARATOR
Intervention: Killed hepatitis A vaccine without aluminium hydroxide as adjuvant
Number of subjects: 32
Study 2565998 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed hepatitis A vaccine (both groups)
Number of subjects: 32
Study 946973 — intervention group
Group type: EXPERIMENTAL
Intervention: Alice influenza virus vaccine
Number of subjects: 47
Study 946973 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet inactivated vaccine
Number of subjects: 47
Study 946973 — intervention group
Group type: COMPARATOR
Intervention: 1:10 dilution of virus
Number of subjects: 47
Study 946973 — intervention group
Group type: COMPARATOR
Intervention: 1:100 dilution of virus
Number of subjects: 47
Study 946973 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibody-negative)
Number of subjects: 47
Study 30811775 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) for 12 weeks at 75% one repetition maximum
Number of subjects: 44
Study 27862855 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 30 IU in 500 ml normal saline
Number of subjects: 80
Study 27862855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pure normal saline)
Number of subjects: 80
Study 26094098 — intervention group
Group type: EXPERIMENTAL
Intervention: Single scrotal incision approach (89 patients, 100 testis)
Number of subjects: 200
Study 26094098 — intervention group
Group type: COMPARATOR
Intervention: Two incisions inguinal approach (80 patients, 100 testis)
Number of subjects: 200
Study 24054187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol
Number of subjects: 16
Study 24054187 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 16
Study 21789650 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-Score SMR protocol
Number of subjects: 12
Study 21789650 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-Score IND protocol
Number of subjects: 12
Study 19674448 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational programme 'Beating Bipolar' via a web‐based system
Number of subjects: 100
Study 19674448 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study 17111019 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 15
Study 17111019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17111019 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study 17111019 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected method
Number of subjects: 15
Study 15079129 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation as primary management
Number of subjects: 13100
Study 15079129 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant postoperative chemoradiation
Number of subjects: 13100
Study 15079129 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation
Number of subjects: 13100
Study 15079129 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes and irinotecan in combinations with platinum compounds and fluoropyrimidines
Number of subjects: 13100
Study 11514813 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SMT
Number of subjects: 36
Study 11514813 — intervention group
Group type: COMPARATOR
Intervention: Sham SMT
Number of subjects: 36
Study 9249122 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA + high‐TAES (9‐12 mA of electrical stimulation)
Number of subjects: 101
Study 9249122 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA + low‐TAES (4‐5 mA of electrical stimulation)
Number of subjects: 101
Study 9249122 — intervention group
Group type: COMPARATOR
Intervention: PCA + sham‐TAES (no electrical stimulation)
Number of subjects: 101
Study 9249122 — intervention group
Group type: COMPARATOR
Intervention: PCA only
Number of subjects: 101